Recent advances in the management of STS



Published
Patrick Schöffski, MD, MPH, KU Leuven, Leuven, Belgium, discusses treatment strategies for soft tissue sarcomas (STS), highlighting heterogeneity of the disease as well as recent advances in the identification of molecular drivers of STS. Prof. Schöffski touches on the development of MDM2-targeting agents as a potential therapeutic avenue for this patient population. This interview took place at the European Society for Medical Oncology (ESMO) 2022 Congress in Paris, France.
Category
Management
Be the first to comment